Extended Data Fig. 5: Impact of polatuzumab vedotin on the pharmacodynamics of mosunetuzumab by assessing the CD4+ and CD8+ change from baseline for A, CD69, B, HLA-DR and C, margination.

Note: T-cell markers (percentages of CD69+ and PD1+ in CD4 and CD8 T cells) and cell counts of CD4 and CD8, in peripheral blood, were measured at baseline, 30 minutes after polatuzumab vedotin dosing and 2 hours after mosunetuzumab at multiple time points. Blood samples from patients treated with 1/2/60/30 mg of mosun-pola, were evaluated for T cell activation and margination, at C1D1-PRE. (n = 88 and 93, respectively), C1D1-Pola (n = 79 and 77), C1D1-Mosun (after pola; n = 82 and 79), C1D15-PRE (n = 41 and 33), C1D15-Mosun (alone) (n = 37 and 27), C2D1-PRE (n = 76, and 76) and C2D1-Mosun (after pola; n = 77 and 75). Box plots represent changes from baseline at each time point in (A) percentages of CD69+CD4+ and CD69 + CD8+ T cells, (B) percentages of HLA-DR + CD4+ and HLA-DR + CD8+ T cells and (C) CD4 and CD8 cell counts (fold changes). Each patient is represented by a filled circle with the colors depicting the best overall responses. The median change in response at each time point is represented by the line. P values represent pairwise two-sided Wilcox test against baseline (C1D1-PRE) (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001). Comparisons with small effect size (r < 0.3) or P > 0.05 are depicted as ns. Box plots show median and quartiles, and whiskers depict the highest and lowest values that are within 1.5 times of inter-quartile range from the upper and lower quartile values. C, cycle; CR, complete response; D, day; mosun, mosunetuzumab; - ns, not-significant (p > 0.05); ORR, objective response rate; PD, progressive disease; PR, partial response; PRE, pre-treatment; pola, polatuzumab vedotin; SD, stable disease.